Mark L. Ragains
Amgen
5 Papers
47 Citations
Mark L. Ragains is an academic researcher from Amgen. The author has contributed to research in topics: Kinase & Leukemia. The author has an hindex of 2, co-authored 5 publications.
Chat about Author
Papers
Patent
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
Xiaoqi Chen,Dai Kang,Jason Duquette,Michael W. Gribble,Justin N. Huard,Kathleen S. Keegan,Zhihong Li,Lively Sarah E,Lawrence R. McGee,Mark L. Ragains,Xianghong Wang,Margaret F. Weidner,Jian Zhang +12 more
- 21 Mar 2012
TL;DR: In this paper, the authors describe compounds of Formula (I) which are useful inhibitors of CDK 4, CDK 6, and FLT3, such compounds are useful in treating cancer and various other disease conditions and have the following structure: where R 1 is a group of formula (IA, Formula (IB), Formula (IC), or Formula (ID) and the definitions of the other variables are provided.
45
Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia
Kathleen S. Keegan,Cong Li,Zhihong Li,Ji Ma,Mark L. Ragains,Suzanne Coberly,David Hollenback,John Eksterowicz,Lingming Liang,Margaret F. Weidner,Justin N. Huard,Xianghong Wang,Grace Alba,Jessica Orf,Mei-Chu Lo,Sharon Zhao,Rachel Ngo,Ada Chen,Lily Liu,Timothy J. Carlson,Christophe Queva,Lawrence R. McGee,Julio C. Medina,Alexander Kamb,Dineli Wickramasinghe,Kang Dai +25 more
TL;DR: Preclinical evaluation of AMG 925, a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor, which combines inhibition of two kinases essential for proliferation and survival ofFLT3-mutated AML cells, may improve and prolong clinical responses.
38
Abstract 2351: CDK4/FLT3 dual inhibitors as potential therapeutics for acute myeloid leukemia.
Zhihong Li,Kang Dai,Kathleen S. Keegan,Ji Ma,Mark L. Ragains,Jacob Kaizerman,Dustin McMinn,Jiasheng Fu,Benjamin Fisher,Michael W. Gribble,Lawrence R. McGee,John Eksterowicz,Cong Li,Lingming Liang,Margaret F. Weidner,Justin N. Huard,Robert Cho,Timothy J. Carlson,Grace Alba,David Hollenback,John S. Hill,Darrin M. Beaupre,Alexander Kamb,Dineli Wickramasinghe,Julio C. Medina +24 more
TL;DR: The hypothesis that simultaneously inhibition of CDK4 and FLT3 may improve the durability of clinical response in AML is supported and consequently that this hypothesis should be tested in the clinic.
2
Patent
Doubles inhibiteurs tricycliques fusionnés de cdk 4/6 et de flt3
Xiaoqi Chen,Kang Dai,Jason Duquette,Michael W. Gribble,Justin N. Huard,Kathleen S. Keegan,Zhihong Li,Sarah E. Lively,Lawrence R. Mcgee,Mark L. Ragains,Xianghong Wang,Margaret F. Weidner,Jian Zhang +12 more
- 21 Mar 2012
TL;DR: Les composes de Formule (I) selon l'invention sont des inhibiteurs utiles de CDK 4, CDK 6 and FLT3.